ArticleGene therapy2006
Efficient infection of tumor endothelial cells by a capsid-modified adenovirus.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells.Biomedicines · 2022Article
- Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Molecular therapy oncolytics · 2022Review
- A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.Cancer biology & therapy · 2017Review
- Targeting tumor vasculature through oncolytic virotherapy: recent advances.Oncolytic virotherapy · 2015Review
- The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.Virology · 2013Article
- Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice.PloS one · 2013Article
- Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5.Virology journal · 2012Article
- Optimizing adenoviral transduction of endothelial cells under flow conditions.Pharmaceutical research · 2012Article
- Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.Cancer gene therapy · 2010Article
- Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart.Histochemistry and cell biology · 2010Article
- Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.Molecular cancer therapeutics · 2009Article
- Article
- Enhanced Gene Delivery to Human Primary Endothelial Cells Using Tropism-Modified Adenovirus Vectors.The open gene therapy journal · 2008Article
- Evaluation of copolymers of N-isopropylacrylamide and 2-dimethyl(aminoethyl)methacrylate in nonviral and adenoviral vectors for gene delivery to nasopharyngeal carcinoma.International journal of nanomedicine · 2007Article
- Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.Cancer gene therapy · 2006Article
- The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy.Human reproduction updateReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted antiangiogenic gene therapy is an attractive approach to treat metastatic cancer. However, the relative paucity of the receptors of the commonly used adenovirus serotype 5 in endothelial cells as compared with liver cells undermines the use of this vector for targeting the endothelial cells in tumors. To overcome this problem, we analyzed the ability of a hybrid Ad5/35 virus, where the serotype 5 fiber has been replaced with the fiber from serotype 35, to target tumor vasculature. Infection of human umbilical vein endothelial cells (HUVECs) with Ad5/35 at MOI 120 infected 100% of cells. In contrast, infection with Ad5 at the same MOI infected only 10% HUVECs. Ad5/35 was even more effective in transducing human aortic endothelial cells (HAECs), as infection with Ad5/35 at MOI 3.6 was sufficient to transduce 95% of cells. Gene expression analyses demonstrated that infection of HUVECs and HAECs with Ad5/35 resulted in between 1 and 3 orders of magnitude higher gene expression than infection with Ad5. Furthermore, various liver-derived cells were less infectable with Ad5/35 than Ad5, indicating a favorable toxicity profile for this virus. In a rat colon carcinoma tumor model, Ad5 was located mainly in the liver parenchyma after hepatic artery administration. In contrast, Ad5/35 was found only in the angiogenesis-rich border region of the tumor. Double immunostaining revealed that Ad5/35 colocalized with CD31 and Flk-1 positive endothelial cells. These results indicate that Ad5/35 may be useful in anticancer strategies targeting tumor endothelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.